XRN1 inhibitors therapy (Accent Therapeutics)

N/A

Report date: 2023/12/07 16:28:10

Base Information

Drug NameXRN1 inhibitors therapy (Accent Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action5'-3' Exoribonuclease 1 inhibitors
Targets5'-3' Exoribonuclease 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAccent Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAccent Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A